Regarding progression-free survival, p120-catenin was a significant prognostic factor in the whole cohort of GBM IDH<sup>wt</sup> patients (HR = 2.542; CI = 1.499-4.312; p<0.001) and in the male patients (HR = 2.431; CI = 1.222-4.836; p=0.011), while SOX10 did not predict the progression-free survival in any group of patients. This evidence concerns the gene SOX10 and glioblastoma.